“…In vivo, using xenograft models, ABT-737 potentiated the effect of a three-drug regimen, with dexamethasone, l-asparaginase and vincristine [25], and delayed leukemia progression in combination with l -asparaginase, topotecan, vincristine or etoposide [21]. Provided reliable predictive markers can be established to select patients that will respond to this drug, addition of ABT-263 to a multidrug regimen with a second-line chemotherapy agent should be investigated with priority.…”